The Role of Neurotrophic Modulation in COPD and Its Influence on Airway Pathophysiology: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.36283/ziun-pjmd14-3/061Keywords:
NGF , BDNF, COPD, Lung Disorders, Neurotrophic Factors, InflammationAbstract
Background: Chronic obstructive pulmonary disease (COPD) is a chronic pulmonary disorder that is characterized by inflammation in the airways and their remodeling. Neurotrophic factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), are seen to potentially contribute to this disease progression. This review synthesized evidence on the potential function of neurotrophic regulation in COPD pathophysiology.
Methods: A systematic review was undertaken by searching PubMed, Scopus, Web of Science, and Embase up to March 2025 for studies that examined neurotrophic factors in COPD. Studies that assessed neurotrophin expression, signaling, or its influence on airway function in COPD patients or animal models were included in this study. Studies that focused on unrelated respiratory disorders, non-neurotrophic biomarkers, or lacked primary data were excluded. Data on the study design, sample size, neurotrophin levels, and major findings were gathered. Meta-analysis was performed using RevMan 5.0.0, and risk of bias was assessed using a modified form of the Evidence Project Risk of Bias Tool.
Results: Of 10 studies included, mixed findings were seen: some reported a rise in NGF and BDNF levels linked to airway inflammation and remodeling, while some found decreased neurotrophin associated with skeletal muscle dysfunction. A pooled effect size of 0.711 [0.553, 0.869] was observed for neurotropic procurement, -0.32 [-0.58, -0.05] for airway remodeling, and 4.26 [2.21, 6.31] for airway inflammation.
Discussion: Neurotrophic factors may contribute to COPD pathophysiology because they influence airway inflammation, remodeling, and muscle dysfunction. Future research should validate the mechanisms that underlie these associations and explore therapeutic targets within neurotrophic pathways.
References
1. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med. 2022 May;10(5):497-511. doi: 10.1016/S2213-2600(21)00506-3.
2. Xu J, Ji Z, Zhang P, Chen T, Xie Y, Li J. Disease burden of COPD in the Chinese population: a systematic review. Ther Adv Respir Dis. 2023 Jan-Dec;17(1):17534666231218899. doi: 10.1177/17534666231218899.
3. Zhu Z, Wu Y, Qu L, Zou Y, Nie G, Xu S, et al. Evaluation of nocturnal apnea and airflow limitation as indicators for cognitive dysfunction in patients with chronic obstructive pulmonary disease/obstructive sleep apnea hypopnea syndrome overlap syndrome. Chron Respir Dis. 2024 Jan-Dec;21(1):14799731241236492. doi: 10.1177/14799731241236492.
4. Dragunas G, Koster CS, de Souza Xavier Costa N, Melgert BN, Munhoz CD, et al. Neuroplasticity and neuroimmune interactions in fatal asthma. Allergy. 2025 Feb;80(2):462-473. doi: 10.1111/all.16373.
5. Liu P, Li S, Tang L. Nerve Growth Factor: A Potential Therapeutic Target for Lung Diseases. Int J Mol Sci. 2021 Aug 24;22(17):9112. doi: 10.3390/ijms22179112.
6. Petrella C, Nenna R, Petrarca L, Tarani F, Paparella R, Mancino E, et al. Serum NGF and BDNF in Long-COVID-19 Adolescents: A Pilot Study. Diagnostics (Basel). 2022 May 7;12(5):1162. doi: 10.3390/diagnostics12051162.
7. Lage VKDS, de Paula FA, Lima LP, Santos JNV, Dos Santos JM, Viegas ÂA, et al. Plasma levels of myokines and inflammatory markers are related with functional and respiratory performance in older adults with COPD and sarcopenia. Exp Gerontol. 2022 Jul;164(1):111834. doi: 10.1016/j.exger.2022.111834.
8. Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020 Jun;33(1):101544. doi: 10.1016/j.redox.2020.101544.
9. Aloe C, Wang H, Vlahos R, Irving L, Steinfort D, Bozinovski S. Emerging and multifaceted role of neutrophils in lung cancer. Transl Lung Cancer Res. 2021 Jun;10(6):2806-2818. doi: 10.21037/tlcr-20-760.
10. James MD, Phillips DB, Elbehairy AF, Milne KM, Vincent SG, Domnik NJ, et al. Mechanisms of Exertional Dyspnea in Patients with Mild COPD and a Low Resting DLCO. COPD. 2021 Oct;18(5):501-510. doi: 10.1080/15412555.2021.1932782.
11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
12. Ogawa H, Azuma M, Umeno A, Shimizu M, Murotomi K, Yoshida Y, et al. Singlet oxygen -derived nerve growth factor exacerbates airway hyperresponsiveness in a mouse model of asthma with mixed inflammation. Allergol Int. 2022 Jul;71(3):395-404. doi: 10.1016/j.alit.2022.02.005.
13. Papp C, Pak K, Erdei T, Juhasz B, Seres I, Szentpéteri A, et al. Alteration of the irisin-brain-derived neurotrophic factor axis contributes to disturbance of mood in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017 Jul 7;12:2023-2033. doi: 10.2147/COPD.S135701.
14. Aranda LC, Ribeiro IC, Freitas TO, Degani-Costa LH, Dias DS, De Angelis K, et al. Altered locomotor muscle metaboreflex control of ventilation in patients with COPD. J Appl Physiol (1985). 2024 Feb 1;136(2):385-398. doi: 10.1152/japplphysiol.00560.2023.
15. Bouchet C, Cardouat G, Douard M, Coste F, Robillard P, Delcambre F, et al. Inflammation and Oxidative Stress Induce NGF Secretion by Pulmonary Arterial Cells through a TGF-β1-Dependent Mechanism. Cells. 2022 Sep 7;11(18):2795. doi: 10.3390/cells11182795.
16. Nenna R, Petrella C, Bonci E, Papoff P, Jorgi MD, Petrarca L, et al. Reduced Serum Brain-Derived Neurotrophic Factor in Infants Affected by Severe Bronchiolitis. Curr Neuropharmacol. 2024;22(14):2433-2442. doi: 10.2174/1570159X22999240223153901.
17. de Araujo CLP, da Silva IRV, Reinaldo GP, Peccin PK, Pochmann D, Teixeira PJZ, et al. Pulmonary rehabilitation and BDNF levels in patients with chronic obstructive pulmonary disease: A pilot study. Respir Physiol Neurobiol. 2018 Jan;259:63-69. doi: 10.1016/j.resp.2018.07.011.
18. Aranda LC, Ribeiro IC, Freitas TO, Degani-Costa LH, Dias DS, DE Angelis K, et al. Enhanced Respiratory Frequency Response to Lower Limb Mechanoreceptors Activation in Patients with Chronic Obstructive Pulmonary Disease. Med Sci Sports Exerc. 2023 Mar 1;55(3):418-429. doi: 10.1249/MSS.0000000000003065.
19. Guo Z, Liu L, Li S, Xu B, Xu Y, Li H. Effect of BDNF on airway inflammation in a rat model of COPD. Exp Ther Med. 2021 Oct;22(4):1116. doi: 10.3892/etm.2021.10550.
20. Karim A, Muhammad T, Qaisar R. Prediction of Sarcopenia Using Multiple Biomarkers of Neuromuscular Junction Degeneration in Chronic Obstructive Pulmonary Disease. J Pers Med. 2021 Sep 15;11(9):919. doi: 10.3390/jpm11090919.
21. Aleksandrova E, Dimov D, Tacheva T, Petrova H, Celik K, Vlaykova T. Smoking-Dependent Association of Serum Brain-Derived Neurotrophic Factor with Pulmonary Function Parameters in Chronic Obstructive Pulmonary Disease. Medicina (Kaunas). 2024 Jul 9;60(7):1111. doi: 10.3390/medicina60071111.
22. Azzoni R, Perdijk O, Harris NL, Marsland BJ. Neuroimmunology of the Lung. Annu Rev Immunol. 2024 Jun;42(1):57-81. doi: 10.1146/annurev-immunol-083122-042512.
23. Tamari M, Ver Heul AM. Neuroimmune mechanisms of type 2 inflammation in the skin and lung. Allergol Int. 2025 Apr;74(2):177-186. doi: 10.1016/j.alit.2025.02.001.
24. Zhang L, Li C, Xiong J, Chang C, Sun Y. Dysregulated myokines and signaling pathways in skeletal muscle dysfunction in a cigarette smoke-induced model of chronic obstructive pulmonary disease. Front Physiol. 2022 Aug 25;13:929926. doi: 10.3389/fphys.2022.929926.
25. Henrot P, Dupin I, Schilfarth P, Esteves P, Blervaque L, Zysman M, et al. Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting. Int J Mol Sci. 2023 Mar 29;24(7):6454. doi: 10.3390/ijms24076454.
26. Raghavan S, Hatipoğlu U, Aboussouan LS. Goals of chronic obstructive pulmonary disease management: a focused review for clinicians. Curr Opin Pulm Med. 2025 Mar 1;31(2):156-164. doi: 10.1097/MCP.0000000000001144.
27. Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021 Sep;20(9):689-709. doi: 10.1038/s41573-021-00233-1.
28. Wiegman CH, Li F, Ryffel B, Togbe D, Chung KF. Oxidative Stress in Ozone-Induced Chronic Lung Inflammation and Emphysema: A Facet of Chronic Obstructive Pulmonary Disease. Front Immunol. 2020 Sep 2;11:1957. doi: 10.3389/fimmu.2020.01957.
29. Schiffers C, Reynaert NL, Wouters EFM, van der Vliet A. Redox Dysregulation in Aging and COPD: Role of NOX Enzymes and Implications for Antioxidant Strategies. Antioxidants (Basel). 2021 Nov 11;10(11):1799. doi: 10.3390/antiox10111799.
30. Guo P, Li R, Piao TH, Wang CL, Wu XL, Cai HY. Pathological Mechanism and Targeted Drugs of COPD. Int J Chron Obstruct Pulmon Dis. 2022 Jul 12;17:1565-1575. doi: 10.2147/COPD.S366126.
31. Cardoso J, Ferreira AJ, Guimarães M, Oliveira AS, Simão P, Sucena M. Treatable Traits in COPD - A Proposed Approach. Int J Chron Obstruct Pulmon Dis. 2021 Nov 18;16:3167-3182. doi: 10.2147/COPD.S330817.
32. Kume H, Yamada R, Sato Y, Togawa R. Airway Smooth Muscle Regulated by Oxidative Stress in COPD. Antioxidants (Basel). 2023 Jan 6;12(1):142. doi: 10.3390/antiox12010142.
33. Pavón-Romero GF, Serrano-Pérez NH, García-Sánchez L, Ramírez-Jiménez F, Terán LM. Neuroimmune Pathophysiology in Asthma. Front Cell Dev Biol. 2021 May 13;9:663535. doi: 10.3389/fcell.2021.663535.
34. Cazzola M, Hanania NA, Page CP, Matera MG. Novel Anti-Inflammatory Approaches to COPD. Int J Chron Obstruct Pulmon Dis. 2023 Jun 29;18:1333-1352. doi: 10.2147/COPD.S419056.
35. Tan CL, Chan Y, Candasamy M, Chellian J, Madheswaran T, Sakthivel LP, et al. Unravelling the molecular mechanisms underlying chronic respiratory diseases for the development of novel therapeutics via in vitro experimental models. Eur J Pharmacol. 2022 Mar 15;919:174821. doi: 10.1016/j.ejphar.2022.174821.
36. Kuiper-Makris C, Fahle L, Zeitouny C, Vohlen C, Klymenko O, Stephan S, et al. BDNF-TrkB Signaling Maintains AT2 Survival and Is Blocked in Hyperoxia-induced Neonatal Lung Injury. Am J Respir Cell Mol Biol. 2025 Apr 8. doi: 10.1165/rcmb.2024-0198OC.
37. Wiegman CH, Li F, Ryffel B, Togbe D, Chung KF. Oxidative Stress in Ozone-Induced Chronic Lung Inflammation and Emphysema: A Facet of Chronic Obstructive Pulmonary Disease. Front Immunol. 2020 Sep 2;11:1957. doi: 10.3389/fimmu.2020.01957.
38. Puteikis K, Mameniškienė R, Jurevičienė E. Neurological and Psychiatric Comorbidities in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2021 Mar 3;16:553-562. doi: 10.2147/COPD.S290363.
39. Zhai Q, Xu K, Li X. Research of related factors of depression in COPD patients. Medicine (Baltimore). 2024 Oct 11;103(41):e40046. doi: 10.1097/MD.0000000000040046.
40. Wing K, Williamson E, Carpenter JR, Wise L, Schneeweiss S, Smeeth L, et al. Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. Eur Respir J. 2021 Mar 25;57(3):2001586. doi: 10.1183/13993003.01586-2020.
41. Mortimer K, Montes de Oca M, Salvi S, Balakrishnan K, Hadfield RM, Ramirez-Venegas A, et al. Household air pollution and COPD: cause and effect or confounding by other aspects of poverty? Int J Tuberc Lung Dis. 2022 Mar 1;26(3):206-216. doi: 10.5588/ijtld.21.0570.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
